Extended Data Fig. 2: LHT improved the delivery and therapeutic effect of clinical nanomedicines.
From: Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours
a, Fluorescent images of mice bearing bilateral orthotropic 4T1 tumours (n = 5 biologically independent samples). b, The accumulated amount of NPs in orthotropic tumours 24 h after injection of NPs (n = 5 biologically independent samples). c, Pseudocolor fluorescence images and corresponding intensity of NPs in LHT-treated tumour sections at different depths (n = 3 biologically independent samples). The results are normalized and shown as a heatmap. d, Fluorescent reflectance imaging of Lipo DOX ( ~ 75 nm) in orthotopic 4T1 tumours. e, Tumoral accumulation of Lipo DOX (n = 4 biologically independent samples). f, Fluorescent images of bilateral 4T1 tumour-bearing mice after control and LXY2 peptide treatments. g, Relative NP accumulation in LHT-treated tumours of mice with or without LXY2 peptide treatment (n = 3 biologically independent samples). h, Therapeutic schedule for bilateral 4T1-Luc tumour-bearing mice. Mice received α-Ly6G and LHT on tumours, followed by i.v. injection of MXT or Lipo MXT (4 mg kg–1). i, Tumour growth curves of mice after different treatments (n = 5 biologically independent samples). P < 1 × 10-15 in Lipo MXT group. j, Therapeutic schedule of bilateral orthotropic 4T1 tumour bearing mice. Mice received LXY2 peptide and LHT, followed by i.v. injection of Lipo DOX (5 mg kg–1). k, Tumour growth curves during the treatments (n = 5 biologically independent samples). P = 7.8 × 10-9 in Lipo DOX group. l, Tumour weight ratios for LHT-treated versus untreated tumours on the same mouse (n = 5 biologically independent samples). P = 3.4 × 10-6 between control and Lipo DOX; P = 5.0 × 10-6 between Lipo DOX and Lipo DOX plus LXY2 peptide. Data in e, g, i, k, and l are presented as mean ± s.d. Significant differences were assessed using a two-tailed unpaired Student’s t-test (b, e, g), a two-way ANOVA with Sidak’s multiple comparisons test (i, k), or a one-way ANOVA with Tukey’s multiple comparison test (l). NS, not significant.
